DK165004B - Sulfamatderivater og farmaceutiske praeparater indeholdende disse - Google Patents

Sulfamatderivater og farmaceutiske praeparater indeholdende disse Download PDF

Info

Publication number
DK165004B
DK165004B DK457784A DK457784A DK165004B DK 165004 B DK165004 B DK 165004B DK 457784 A DK457784 A DK 457784A DK 457784 A DK457784 A DK 457784A DK 165004 B DK165004 B DK 165004B
Authority
DK
Denmark
Prior art keywords
sulfamate
formula
sub
alkyl
hydrogen
Prior art date
Application number
DK457784A
Other languages
English (en)
Other versions
DK165004C (da
DK457784D0 (da
DK457784A (da
Inventor
Bruce Eliot Maryanoff
Joseph Francis Gardocki
Original Assignee
Mcneilab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24134409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK165004(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mcneilab Inc filed Critical Mcneilab Inc
Publication of DK457784D0 publication Critical patent/DK457784D0/da
Publication of DK457784A publication Critical patent/DK457784A/da
Priority to DK199101982A priority Critical patent/DK173923B1/da
Publication of DK165004B publication Critical patent/DK165004B/da
Application granted granted Critical
Publication of DK165004C publication Critical patent/DK165004C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Hydrogenated Pyridines (AREA)

Description

i
DK 165004 B
Sulfamater med forskellige strukturer, inklusive sådanne, der afledes af monosaccharider, er beskrevet i referencer såsom N.K.
Kochetkow, et al., i Zhurnal Obshchei Kimii, bind 41, nr. 8, 1866-1871 (1971), bind 42, nr. 12, 2755-2757 (1972) og bind 44, nr. 4, 871-875 5 (1974), og i Doklady Akademii Nauk SSR, bind 216, nr. 1, 97-100 (1974); T. Tsuchiya et al., i Tetrahedron Letters, nr. 36, 3365-3368 (1978); og A.F. Hirsch i Journal of Medicinal Chemistry, 24, 901-903 (1981), samt US-patentskrift nr. 4.075.351.
Det har nu vist sig, at sulfamater med formel (I) 10 Γ~x. .CH,OSO.NHR, ’•VN 111 R, Ri hvori X er 0 eller CH2 og Rj, R2, R3, R4 og Rg er som defineret i det 15 følgende, besidder anti-konvulsivisk aktivitet i pattedyr og derfor er anvendelige til behandling af sygdomstilstande såsom epilepsi og glau-kom. Den foreliggende opfindelse angår hidtil ukendte sulfamater med formlen (I) 2° r,^ch„, (i)
Rj hvori X er CH2 eller oxygen.
25 Rj er hydrogen eller al kyl, og
Rj>, R3, R4 og Rj, uafhængigt af hinanden, er hydrogen eller lavere alkyl og, når X er CH2, er R4 og Rg eventuelt alkengrupper, der tilsammen danner en benzenring og, når X er oxygen, danner R2 og R3 og/eller R4 og Rg eventuelt en methylendioxygruppe med formel (II) 30 (il) R, O- V- 35 hvori
Rg og R^, som er ens eller forskellige, er hydrogen, lavere al kyl eller al kyl, som tilsammen danner en cyclopentyl- eller cyclohexylring. Opfindelsen angår endvidere et farmaceutisk præparat, som er
DK 165004 B
2 ejendommeligt ved det i den kendetegnende del af krav 9 angivne.
Rj er især hydrogen eller al kyl med 1 til 4 carbonatomer såsom methyl, ethyl og isopropyl. I hele beskrivelsen betyder "alkyl" lige-kædede og forgrenede al kyl grupper. Specifikke alkylgrupper for R2, R3, 5 R4, Rg, Rg og Rj omfatter methyl, ethyl, isopropyl og n-propyl. Når X er CHg, kan R4 og Rg kombineres til dannelse af en benzenring, der er fusioneret til den 6-leddede, X-holdige ring, dvs. at R4 og Rg definerer al katrienylgruppen =CH-CH=CH-CH=.
En speciel gruppe forbindelser med formel (I) er sådanne, hvori X 10 er oxygen og både R2 og R3 og R4 og Rg tilsammen danner methyl endioxy-grupper med formel (II), hvori Rg og R7 begge er hydrogen og al kyl eller tilsammen danner en spiro-cyclopentyl- eller cyclohexylring, især, når Rg og R^ begge er al kyl såsom methyl. En anden gruppe forbindelser er sådanne, hvori X er CH2 og R4 og Rg danner en benzenring. En tredje 15 gruppe forbindelser med formel (I) er sådanne, hvori både R2 og R3 er hydrogen.
Forbindelserne med formel (I) kan syntetiseres ved hjælp af følgende fremgangsmåder: a) Omsætning af en alkohol med formlen RCHgOH med et chlorsulfamat 20 med formlen C1S02NH2 eller CISOgNHRj i nærværelse af en base såsom kalium-t-butoxid eller natriumhydrid ved en temperatur på ca. -20 til 25°C og i et opløsningsmiddel såsom toluen, THF eller dimethyl formamid, hvori R har formlen (III) p /"V (III)
25 R,vA
R, R, b) omsætning af en alkohol med formlen RCH20H med sulfurylchlorid med formlen S02C12 i nærværelse af en base såsom triethylamin eller 30 pyridin ved en temperatur på ca. -40 til 25°C i et opløsningsmiddel såsom diethyl ether eller methylenchlorid til dannelse af et chlorsulfat med formi en RCHgOSOgCl.
Chl orsulfatet med formlen RCH20$02C1 kan dernæst omsættes med en amin med formlen RjNH2 ved en temperatur på ca. -40 til 25°C i et opløs-35 ningsmiddel såsom methylenchlorid eller acetonitril til dannelse af en forbindelse med formel (I). Omsætningsbetingelserne for b) er også beskrevet af T. Tsuchiya, et al., i Tet. Letters, nr. 36, side 3365-3368 (1978).
DK 165004 B
3 c) Omsætning af chlorsulfatet RCHgOSOgCl med et metalazid såsom natriumazid i et opløsningsmiddel såsom methylenchlorid eller acetoni-tril giver et azidosulfat med formlen RCHgOSOgN^ som beskrevet af M.
Hedayatul1 ah i Tet. Lett., side 2455-2458 (1975). Az i dosulfatet reduce-5 res dernæst til en forbindelse med formel (I), hvori Rj er hydrogen, ved katalytisk hydrogenering, fx. med et ædelmetal og Hg eller ved opvarmning med kobbermetal i et opløsningsmiddel såsom methanol.
Udgangsforbindelserne med formlen RCHgOH kan fås kommercielt eller som kendt i teknikken. Eksempelvis kan udgangsforbindelser med formlen 10 RCHgOH, hvori både Rg og Rj og R^ og Rg er identiske og har formlen (II), opnås ved fremgangsmåderne ifølge R.F. Brady i Carbohydrate Research, bind 15, side 35-40 (1970), eller ved omsætning af trimethyl-silylenoletheren af en RgCOR^-keton eller -aldehyd med fruktose ved en temperatur på ca. 25°C i et opløsningsmiddel såsom et halogencarbon, fx.
15 methylenchlorid, i nærværelse af en protisk syre såsom saltsyre eller en Lewis-syre såsom zinkchlorid. Trimethylsilylenoletherreaktionen er beskrevet af G. L. Larson et al i J. Org. Chem., bind 38, nr. 22, side 3935 (1973).
Desuden kan carboxylsyrer og aldehyder med formlen RCOOH og RCHO 20 reduceres til forbindelser med formel RCHgOH ved standard-reduktionsteknikker, fx. omsætning med lithiumaluminiumhydrid, natriumborhydrid eller boran-THF-kompleks i et inert opløsningsmiddel såsom diglyme, THF eller toluen ved en temperatur fra ca. 0 til 100°C, fx. som beskrevet af H.O.
House i "Modern Synthetic Reactions", 2. oplag, side 45-144 (1972).
25 Forbindelserne ifølge opfindelsen omfatter forskellige individuelle isomere samt racematerne deraf, fx. de forskellige forbindelser, hvori Rg, Rj, R^ og Rg er bundet i alfa- eller beta-stilling i forhold til den 6-leddede ring, dvs. under og over tegningens plan. Fortrinsvis er methylendioxygruppens (II) oxygener bundet på samme side af den 6-30 leddede ring.
Forbindelserne med formel (I) er nyttige som antikonvulsiviske midler. Den antikonvulsiviske aktivitet af forbindelserne ifølge opfindelsen bestemtes under anvendelse af en standard "maksimal elektrochock-test" (MES). I denne test indikeres aktivitet ved en 35 blokering af den toniske ekstensor-spasme, der frembringes ved påføring af et elektrisk chock til mus via hornhindeelektroder som beskrevet af Swinyard, et al., i J. Pharmacol. Exptl. Therap. 106, 319 (1952), og anføres som % blokering. En nyere beskrivelse af nu-
DK 165004B
4 tidig antikonvulsivisk lægemiddel-screening kan findes i Swinyard, et al., Epilepsia 19, 409 (1978).
Den antikonvulsiviske aktivitet af forbindelser ifølge opfindelsen, der testes iht. Swinyard-metoden (1952), vises i den følgende tabel (I): 5
Tabel (I)
Eksempel Forbindelse MES-test EDgg *(mg/kg, i.p.) 1 /—o 19 5 10 / Vch,oso,nh, _. CH, 2 Ο-,Ο.Ο,ΝΗ, 270 15 . _o CHjOSOjNH, 3 ch>'Z/^Vch‘ 26 CH, CH· 20 J 0^pH,0S0,NHCH, 70% blok ved 200 mg/kgj i p CH, CH» ch2oso,nh, 5' \ / 55
25 K
*Medmindre andet er anført.
30 Til behandling af epilepsi kan der i et voksent gennemsnitsmenneske anvendes en forbindelse med formel (I) i en daglig dosering i området fra ca. 30 til 2000 mg, sædvanligvis i 2 til 4 doser. En enhedsdosis indeholder ca. 10 til 500 mg aktiv bestanddel.
Almindeligvis kan forbindelser med formel (I) anvendes til 35 behandling af epilepsi på en måde, der ligner den, der anvendes med phenytoin. Medicinske aspekter af behandlingen af epilepsi er beskrevet af L.S. Goodman, et al., i "The Pharmacological Basis of Therapeutics", 5. oplag, s. 201-226, Macmillan (1975).
5
Desuden inhiberer forbindelser med formel (I) carbonsyreanhydrase, som vist ved de af S.J. Dodgson. et al., i The Proc. Natl. Acad. Sci., USA, 77, s. 5562-5566 (1980) eller af N. Itada, et al., i The Journal Biol. Chem., 252, s. 3881-3890 (1977) beskrevne fremgangsmåder og er som 5 sådanne anvendelige til behandling af glaukom. Sammenhængen mellem behandling af glaukom og carbonsyreanhydrase-inhibering er beskrevet af A. Stein, et al., i The American Journal of Opthalmology, 95:222-228 (1983). Til behandling af glaukom kan en forbindelse med formel (I) administreres systemisk, fx. ad oral eller parenteral vej som beskrevet 10 nedenfor, eller topisk i øjet som en mineralolieopløsning eller -suspension, eller vandig suspension. Når forbindelsen anvendes systemisk, administreres den i en mængde fra ca. 50 til 500 mg per dag for et voksent gennemsnits-menneske, mens den topiske dosering er ca. 1 til 3 dråber (per øje) af en opløsning eller suspension, der indeholder ca. 1 til 15 5 vægt-% af en forbindelse med formel (I), idet dosen administreres ca.
1 til 4 gange daglig.
Til fremstilling af de farmaceutiske præparater ifølge opfindelsen blandes én eller flere sulfamatforbindel ser med formel (I) grundigt med en farmaceutisk bærer iht. konventionelle farmaceu-20 tiske sammenbland!ngsteknikker, idet bæreren kan være på mange forskellige former i afhængighed af den til administreringen ønskede præparatform, fx. oral, ved suppositorier eller parenteral. Ved fremstilling af præparaterne i oral dosisform kan der anvendes et hvilket som helst af de sædvanlige farmaceutiske medier. Egnede 25 bærere og tilsætningsstoffer for flydende orale præparater som fx suspensioner, elikserer og opløsninger omfatter således vand, gly-koler, olier, alkoholer, smagsstoffer, konserveringsmidler, farvestoffer o.l., for faste orale præparater såsom fx. pulvere, kapsler og tabletter omfatter egnede bærere og tilsætningsstoffer, stivelser, 30 sukkerarter, fortyndere, granuleringsmidler, smøremidler, bindemidler, disintegreringsmidler o.l. P.g.a. den lette administrering udgør tabletter og kapsler den mest fordelagtige orale enhedsdosisform, i hvilket tilfælde der selvfølgelig anvendes faste farmaceutiske bærere. Om ønsket kan tabletter sukkerovertrækkes eller overtræk-35 kes enterisk ved hjælp af standardteknikker. Der kan fremstilles suppositorier, i hvilket tilfælde kakaosmør kan anvendes som bærer.
Ved parenterale præparater omfatter bæreren sædvanligvis sterilt vand, selvom andre bestanddele kan inkluderes, fx med hensigten
DK 165004B
6 såsom at forbedre opløseligheden eller holdbarheden. Der kan også fremstilles injicerbare suspensioner, i hvilket tilfælde der kan anvendes passende flydende bærere, suspensionsmidler o.l.
Det farmaceutiske præparater ifølge opfindelsen vil pr. enheds-5 dosis fx. tabletter, kapsler, pulvere, injektioner, teskefuld, suppositorier o.l. indeholde fra ca. 10 til ca. 500 mg aktiv bestanddel.
De ovennævnte foregående præparater er specielt egnede til anvendelse ved behandling af epilepsi eller epilepsi-symptomer ved hjælp af en fremgangsmåde, der omfatter intern administrering til en 10 patient, der lider af epilepsi-symptomer, idet præparaterne omfatter en effektiv epilepsi-inhiberende mængde af en forbindelse med formel (I).
I de følgende eksempler og i hele beskrivelsen anvendes følgende forkortelser: g (gram), ml (milliliter), cm (centimeter), v/v (volumen til volumen), smp. (smeltepunkt), TLC (tyndtlagskromatografi), NMR 15 (kernemagnetisk resonans), IR (infrarød), DMF (dimethylformamid), THF (tetrahydrofuran) og C, Η, N, etc. (de kemiske symboler for grundstofferne).
Eksempel 1 20 (Tetrahydro-2H-pyran-2-yl)methansulfamat
Til en kold opløsning (-5°C) af tetrahydropyran-2-methanol (2,33 g, 0,02 mol) i DMF (40 ml) sattes 50% olieagtigt natriumhydrid (1,17 g, 0,024 mol som NaH). Efter omrøring i 45 minutter tilsattes sulfamoylchlorid (3,42 g, 0,03 mol) og omrøringen fortsattes i yderi ige-25 re 45 minutter ved -5°C. Reaktionsblandingen hældtes i koldt vand og ekstraheredes med chloroform. Det organiske lag tørredes (Na2S04) og opløsningsmidlerne fjernedes under vakuum, hvilket gav en sirup, der kro-matograferedes på tør kolonne (der elueredes med ethyl acetat:hexan, 4:1 v/v), hvilket gav rent (tetrahydro-2H-pyran-2-yl)methansulfamat som en 30 svagt gul sirup, IR:(CHCl^) 1180 cm"1 og 1370 cm"1 (OSOgNHg).
Eksempel 2 (1-methylcyclohexyl)methansulfamat
Til en kold opløsning (-4°C) af (1-methylcyclohexyl)methanol (6,2 35 g, 0,048 mol) i DMF (90 ml) sattes 50% olieagtigt natriumhydrid (82,81 g, 0,059 mol som NaH). Efter omrøring i 1 time tilsattes sulfamoylchlo-rid (7,82 g, 0,062 mol) og omrøringen fortsattes i yderligere 30 minutter ved -4°C. Reaktionsblandingen hældtes i koldt vand og ekstraheredes
DK 165004 B
7 med toluen. Det organiske lag tørredes (Na2S04) og opløsningsmidlerne fjernedes under vakuum, hvilket gav en sirup, der krystalliserede efter afkøling. Omkrystallisation fra chloroform/ hexan gav rent (1-methyl-cyclohexyljmethansulfamat, smp. 40-42°C.
5
Eksempel 3 2,3:4,5-bi s-0-(1-methyl ethyl i den)-β-O-fruktopyranosesulfamat
Til en kold opløsning (-4°C) af 2,3:4,5-di-0-isopropyliden-/3-fruk-topyranose (75 g, 0,29 mol) i DMF (725 ml) sattes 50% olieagtigt natri -10 umhydrid (16,34 g, 0,34 mol som NaH). Efter omrøring i 90 minutter tilsattes sulfamoylchlorid (54,9 g, 0,48 mol) og omrøringen fortsattes i yderligere 3½ time ved denne temperatur. Reaktionsblandingen hældtes i koldt vand og ekstraheredes med toluen. Det organiske lag tørredes (Na2S04) og opløsningsmidlerne fjernedes under vakuum, hvilket gav en 15 sirup, som øjeblikkeligt krystalliserede. Omkrystallisation fra ethyl -acetat/hexan gav rent 2,3:4,5-bis-0-(l-methylethyliden)-/J-D-fruktopyra-nosesulfamat, smp. 125-126°C.
Eksempel 4 20 2,3:4,5-bi s-0- (1 -methylethyl iden) -jS-D-fruktopyranosemethyl sul famat En opløsning af sulfonylchlorid (93 ml, 1,15 mol) i methylen-chlorid (100 ml) sattes dråbevis til en kold opløsning (-35°C) af 2,3:4,5-di-0-isopropyliden-/3-D-fruktopyranose (150 g, 0,58 mol) i methylenchlorid (400 ml) og pyridin (150 ml). Reaktionsblandingen 25 omrørtes og opvarmedes til stuetemperatur (25°C); den omrørtes i yderligere 2 timer. Opløsningsmidler fjernedes under vakuum. Det resulterende halvfaste stof opløstes i vandfri acetonitril (35 g, 150 ml) og methylamin bobledes igennem. Reaktionsbeholderen lukkedes tæt og opløsningsmidler fjernedes under vakuum. Den resulterende sirup 30 underkastedes væskekromatografi (tør kolonne ethyl acetat: hexan, 4:1), hvilket gav en lysegul sirup, 2,3:4,5-bis-0-(l-methylethyliden)-j3-D-fruktopyranosemethylsul famat, som var homogent ifølge TLC og *H NHR.
Eksempel 5 35 (l,2,3,4-tetrahydro-2-naphthalenyl)methylsulfamsyreester
Til en kold opløsning (-5°) af (l,2,3,4-tetrahydro-2-naphthalenyl)-methanol (7,1 g, 0,044 mol) i DMF (80 ml) sattes 50% olieagtigt natriumhydrid (2,56 g, 0,054 mol som NaH). Efter omrøring i 45 minutter

Claims (10)

1. Sul famater med formlen (I)
15 R ^“^CH.OSO^HR, (I) hvori R|1 Rj X er CH2 eller oxygen. Rj er hydrogen eller al kyl, og
20 R2, Rg, R4 og Rg uafhængigt af hinanden er hydrogen eller lavere alkyl og, når X er CH2, er R^ og Rg eventuelt alkengrupper, der tilsammen danner en benzenring og, når X er oxygen, danner R2 og Rg og/eller R^ og Rg eventuelt en methylendioxygruppe med formel (II)
25 V0_ <U> r{ \>- hvori Rg og Ry, som er ens eller forskellige, er hydrogen, lavere al kyl, eller al kyl som tilsammen danner en cyclopentyl- eller cyclohexylring. 30
2. Sulfamat ifølge krav 1, kendetegnet ved, at X er oxygen og R2 og Rg og R^ og Rg tilsammen danner methylendioxygrupper med formlen (II), hvor Rg og Ry er som defineret ovenfor.
3. Sulfamat ifølge krav 1, kendetegnet ved, at X er CH2 og R^ og Rg er alkengrupper, der tilsammen danner en benzenring. DK 165004B
4. Sulfamat ifølge krav 3, kendetegnet ved, at R2 og Rg er hydrogen.
5. Sulfamat ifølge krav 1, kendetegnet ved, at 5 alkylgruppen for Rj er al kyl med 1 til 4 carbonatomer, den lavere al kyl -gruppe for R2, Rg, R4 og Rg er al kyl med 1 til 3 carbonatomer og den lavere al kyl for Rg og R^ er alkyl med 1 til 3 carbonatomer.
6. Sulfamat ifølge krav 1, kendetegnet ved, at det er ud- 10 valgt fra gruppen bestående af (tetrahydro-2H-pyran-2-yl)methansulfamat, (1-methylcyclohexylJmethansulfamat, 2,3:4,5-bis-0-(l-methyl ethyl i den)-β-ΰ-fruktopyranosesulfamat, 2,3:4,5-bis-0-(l-methyl ethyl i den)-/1-D-fruktopyranosemethy1 sul famat, 15 og (1,2,3,4-tetrahydro-2-napthalenyl)methylsulfamsyreester.
7. Sulfamat ifølge krav 6, kendetegnet ved, at det er 2,3:4,5-bi s-0-(1-methylethyl iden)-β-Ό-fruktopyranosesulfamat. 20
8. Sulfamat ifølge krav 6, kendetegnet ved, at det er (1,2,3,4-tetrahydro-2-naphthalenylJmethylsulfamsyreester.
9. Farmaceutisk præparat, kendetegnet ved, at det 25 omfatter et sulfamat ifølge krav 1 og en farmaceutisk acceptabel bærer.
10. Farmaceutisk præparat ifølge krav 9, kendetegnet ved, at sulfamatet er til stede i en enhedsdosismængde fra ca. 10 til 500 mg sulfamat. 30
DK457784A 1983-09-26 1984-09-25 Sulfamatderivater og farmaceutiske praeparater indeholdende disse DK165004C (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK199101982A DK173923B1 (da) 1983-09-26 1991-12-09 Azidosulfat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53547583 1983-09-26
US06/535,475 US4513006A (en) 1983-09-26 1983-09-26 Anticonvulsant sulfamate derivatives

Publications (4)

Publication Number Publication Date
DK457784D0 DK457784D0 (da) 1984-09-25
DK457784A DK457784A (da) 1985-03-27
DK165004B true DK165004B (da) 1992-09-28
DK165004C DK165004C (da) 1993-02-08

Family

ID=24134409

Family Applications (3)

Application Number Title Priority Date Filing Date
DK457784A DK165004C (da) 1983-09-26 1984-09-25 Sulfamatderivater og farmaceutiske praeparater indeholdende disse
DK198191A DK165003C (da) 1983-09-26 1991-12-09 Chlorsulfat
DK199101982A DK173923B1 (da) 1983-09-26 1991-12-09 Azidosulfat

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK198191A DK165003C (da) 1983-09-26 1991-12-09 Chlorsulfat
DK199101982A DK173923B1 (da) 1983-09-26 1991-12-09 Azidosulfat

Country Status (18)

Country Link
US (1) US4513006A (da)
EP (1) EP0138441B1 (da)
JP (2) JPS60109558A (da)
KR (1) KR920001775B1 (da)
AT (1) ATE36149T1 (da)
AU (1) AU564842B2 (da)
CA (1) CA1241951A (da)
DE (1) DE3473143D1 (da)
DK (3) DK165004C (da)
ES (1) ES8602634A1 (da)
FI (1) FI79095C (da)
HU (1) HU194540B (da)
IE (1) IE57684B1 (da)
MX (1) MX9202630A (da)
NL (1) NL990025I2 (da)
NO (2) NO170280C (da)
NZ (1) NZ209494A (da)
ZA (1) ZA847550B (da)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
PT94305B (pt) * 1989-06-12 1997-02-28 Robins Co Inc A H Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6903084B2 (en) 1991-08-29 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5498629A (en) * 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
DE69434652T2 (de) * 1993-12-23 2007-03-01 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive pseudofructopyranose sulfamate
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
KR970027051A (ko) * 1995-11-02 1997-06-24 조규향 카바모일기를 포함하는 신규한 설파메이트 화합물
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
WO1998000129A2 (en) * 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1998000124A1 (en) * 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
AP1285A (en) * 1996-06-28 2004-06-24 Ortho Mcneil Pharm Inc Anticonvulsant sulfamate derivatives useful in treating obesity.
ATE226071T1 (de) * 1996-10-08 2002-11-15 Ortho Mcneil Pharm Inc Antikonvulsive derivate zur behandlung von neuropathischem schmerz
JP3744089B2 (ja) * 1996-12-02 2006-02-08 富士電機ホールディングス株式会社 マグネトロンスパッタ成膜装置および成膜方法
US5760006A (en) * 1997-06-23 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
JP2002527470A (ja) * 1998-10-20 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド アルコール依存症、中毒及び乱用の処置に有用な抗痙攣剤誘導体
US6472370B1 (en) 1998-11-17 2002-10-29 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating post traumatic stress disorder
DK1143967T3 (da) * 1999-01-19 2005-01-10 Ortho Mcneil Pharm Inc Anticonvulsive derivater egnede til behandling af Hortons hovedpine
AR022321A1 (es) * 1999-01-21 2002-09-04 Ortho Mcneil Pharm Inc Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
TR200102205T2 (tr) * 1999-02-01 2002-01-21 Ortho-Mcneil Pharmaceutical, Inc. Anti-konvülsan türevlerinin bulimia nevruza tedavisinde kullanılmaları.
ATE299371T1 (de) * 1999-02-08 2005-07-15 Ortho Mcneil Pharm Inc Antikonvulsiva zur behandlung von autismus
AU779823B2 (en) * 1999-02-17 2005-02-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating essential tremor
ES2238999T3 (es) * 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
AU774732B2 (en) * 1999-04-08 2004-07-08 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
NZ514811A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
CA2369091C (en) * 1999-04-08 2005-01-11 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering blood pressure
WO2000061140A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
JP2002543123A (ja) * 1999-04-30 2002-12-17 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド コカイン依存症の処置において有用な抗痙攣性誘導体
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
JP2003500444A (ja) * 1999-05-28 2003-01-07 ジェフリー バーラント， 心的外傷後ストレス障害の処置のための化合物および方法
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
DK1187603T3 (da) 1999-06-14 2007-12-17 Vivus Inc Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
AU782759B2 (en) * 1999-08-20 2005-08-25 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
US7335650B2 (en) * 2000-01-14 2008-02-26 Sterix Limited Composition
SE0000601D0 (sv) 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
ATE320805T1 (de) * 2000-07-07 2006-04-15 Ortho Mcneil Pharm Inc Antikonvulsive derivate zur behandlung und vorbeugung der entwicklung von typ ii diabetes und syndrom x
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
WO2002009694A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
DK1333887T3 (da) 2000-10-30 2006-11-13 Ortho Mcneil Pharm Inc Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
PL365378A1 (en) 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
PT1337271E (pt) 2000-11-30 2005-01-31 Pfizer Prod Inc Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase
WO2002064085A2 (en) * 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
JP2004331502A (ja) * 2001-06-18 2004-11-25 Ortho Mcneil Pharmaceut Inc 視神経細胞保護剤
UA78211C2 (en) * 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
EP1450826A1 (en) * 2001-11-06 2004-09-01 Ortho-Mcneil Pharmaceutical Corp. Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003213242A1 (en) * 2002-02-26 2003-09-09 Ortho-Mcneil Pharmaceutical Inc. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US7060725B2 (en) * 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP2301537A1 (en) * 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1515703A1 (en) * 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20050175697A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms of topiramate
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US20040115262A1 (en) * 2002-07-29 2004-06-17 Frank Jao Formulations and dosage forms for controlled delivery of topiramate
EP1545546B1 (en) * 2002-09-13 2007-04-04 Motac Neuroscience Limited Treatment of dyskinesia with 2,3-benzodiazepines
DE60313474T2 (de) * 2002-09-17 2008-01-03 Motac Neuroscience Ltd. Behandlung von dyskinesie
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7196209B2 (en) * 2002-10-31 2007-03-27 Ortho-Mcneil Pharmaceutical, Inc. Continuous process for the preparation of fructopyranose sulfamate derivatives
US7208477B2 (en) * 2002-12-02 2007-04-24 University Of Florida Research Foundation, Inc. Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
BR0317177A (pt) 2002-12-13 2005-10-25 Cilag Ag Preparações de liberação controlada compreendendo tramadol e topiramato
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
UA81657C2 (ru) * 2003-03-04 2008-01-25 Орто-Макнейл Фармасьютикел, Инк. Способ получения противосудорожных производных топирамата
WO2004089965A2 (en) * 2003-04-07 2004-10-21 Cipla Ltd Topiramate and processes for the preparation thereof
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
WO2004108732A1 (en) * 2003-05-12 2004-12-16 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF 2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ß-D-FRUCTOPYRANOSE SULFAMATE
MXPA05012317A (es) 2003-05-16 2006-01-30 Pfizer Prod Inc Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
EP1653922A2 (en) * 2003-08-06 2006-05-10 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
AU2004268549A1 (en) * 2003-08-22 2005-03-10 Alza Corporation Stepwise delivery of topiramate over prolonged period of time
BRPI0413881A (pt) * 2003-08-28 2006-10-24 Sandoz Ag composição farmacêutica compreendendo anticonvulsivante com revestimento de mascaramento de gosto
EP1701697A2 (en) * 2003-09-02 2006-09-20 ALZA Corporation Novel drug compositions and dosage forms of topiramate
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP1684713A1 (en) * 2003-11-14 2006-08-02 ALZA Corporation Controlled release of topirimate in liquid dosage forms
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
JP2007517061A (ja) * 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 新規薬剤組成物及び投与形態物
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007537151A (ja) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
US20050203287A1 (en) * 2004-03-11 2005-09-15 Chandrasekhar Batchu Process for the preparation of sulfamate derivatives
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PL1627881T3 (pl) * 2004-08-19 2006-11-30 Helm Ag Sposób otrzymywania topiramatu
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
JP4912312B2 (ja) * 2004-08-24 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
CN101257889A (zh) * 2005-05-25 2008-09-03 詹森药业有限公司 托吡酯的儿科制剂
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US20070123578A1 (en) * 2005-09-23 2007-05-31 Fina Liotta Hexahydro-cycloheptapyrazole cannabinoid modulators
BRPI0616263A2 (pt) * 2005-09-23 2011-06-14 Janssen Pharmaceutica Nv moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
UA93389C2 (en) * 2005-09-23 2011-02-10 Янссен Фармацевтика H.B. Hexahydro cyclooctyl pyrazole cannabinoid modulators
EP1940411A4 (en) * 2005-09-29 2008-10-29 Janssen Pharmaceutica Nv MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US7526911B2 (en) * 2006-02-03 2009-05-05 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
TW200738669A (en) * 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
WO2007099388A1 (en) * 2006-03-01 2007-09-07 Glade Organics Private Limited An improved process for the manufacture of topiramate
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009529575A (ja) * 2006-03-10 2009-08-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのピリジン−含有大複素環式化合物
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US20070293476A1 (en) * 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
WO2008010231A2 (en) * 2006-05-26 2008-01-24 Alembic Limited A process for the purification of topiramate
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
EP2061458B1 (en) * 2006-09-15 2014-12-10 Regents of the University of Minnesota Topiramate compositions and methods for their use
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
KR20140088619A (ko) * 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
AU2007329373B2 (en) 2006-12-04 2013-06-20 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
AR070949A1 (es) * 2007-10-19 2010-05-19 Solvay Pharm Gmbh Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
EA201071120A1 (ru) * 2008-03-26 2011-06-30 Янссен Фармацевтика Н.В. Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
CA2729056A1 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2758302C (en) * 2009-05-08 2014-12-02 Georgia State University Research Foundation, Inc. Compounds and compositions comprising cdk inhibitors and methods for treatment of cancer
KR101841442B1 (ko) * 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
JP5643844B2 (ja) 2010-02-05 2014-12-17 サイノファーム タイワン リミテッド トピラマート（ｔｏｐｉｒａｍａｔｅ）の製造方法
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
AU2014228861B2 (en) 2013-03-15 2018-05-24 Aprecia Pharmaceuticals LLC Rapidly dispersible dosage form of topiramate
CN103910770B (zh) * 2014-03-14 2017-01-04 天津南开允公医药科技有限公司 一种托吡酯的制备方法以及该方法中所涉及的中间体晶型及其制备方法
US20220016074A1 (en) 2018-11-21 2022-01-20 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997585A (en) * 1974-12-30 1976-12-14 Ortho Pharmaceutical Corporation Aliphatic sulfamates

Also Published As

Publication number Publication date
KR920001775B1 (ko) 1992-03-02
JPH055824B2 (da) 1993-01-25
FI843765A0 (fi) 1984-09-25
DE3473143D1 (de) 1988-09-08
EP0138441A2 (en) 1985-04-24
HU194540B (en) 1988-02-29
NO170280C (no) 1992-09-30
FI79095C (fi) 1989-11-10
DK198191D0 (da) 1991-12-09
NL990025I1 (nl) 1999-11-01
IE57684B1 (en) 1993-02-24
NZ209494A (en) 1987-03-06
NL990025I2 (nl) 1999-12-01
KR850002264A (ko) 1985-05-10
NO1997004I1 (no) 1997-05-09
JPH05331132A (ja) 1993-12-14
DK165004C (da) 1993-02-08
HUT36784A (en) 1985-10-28
CA1241951A (en) 1988-09-13
FI843765L (fi) 1985-03-27
DK173923B1 (da) 2002-02-18
EP0138441B1 (en) 1988-08-03
DK457784D0 (da) 1984-09-25
IE842444L (en) 1985-03-26
DK165003B (da) 1992-09-28
ES536225A0 (es) 1985-11-16
ATE36149T1 (de) 1988-08-15
MX9202630A (es) 1992-06-30
AU564842B2 (en) 1987-08-27
NO843836L (no) 1985-03-27
DK198291D0 (da) 1991-12-09
JPS60109558A (ja) 1985-06-15
DK198291A (da) 1991-12-09
DK198191A (da) 1991-12-09
AU3350484A (en) 1985-04-04
DK457784A (da) 1985-03-27
FI79095B (fi) 1989-07-31
NO170280B (no) 1992-06-22
EP0138441A3 (en) 1986-08-27
ES8602634A1 (es) 1985-11-16
US4513006A (en) 1985-04-23
DK165003C (da) 1993-02-08
ZA847550B (en) 1986-05-28

Similar Documents

Publication Publication Date Title
DK165004B (da) Sulfamatderivater og farmaceutiske praeparater indeholdende disse
US4792569A (en) Anticonvulsant phenethyl sulfamates
KR100241860B1 (ko) 약제학적으로 유용한 항경련제 설파메이트의 이미데이트 유도체
US5242942A (en) Anticonvulsant fructopyranose cyclic sulfites and sulfates
EP0370415B1 (de) Quinuclidine, ihre Verwendung als Arzneimittel und Verfahren zu ihrer Herstellung
US5384327A (en) Anticonvulsant sorbopyranose sulfamates
CA1252109A (en) Anticonvulsant dioxolane methane sulfamates
US4582916A (en) Chlorosulfate and azidosulfate esters of tetrahydro-2H-pyran-2-yl-methanol
DE69524186T2 (de) Tricyclische Amidverbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DE69605856T2 (de) Alkoxyarylverbindungen mit Affinität zu den Melatoninrezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DE69227366T2 (de) Durch 2- und 5- Alkyl und Phenyl substituierte 4-(1-hydroxy, 1-acyloxy oder 1-carbamoyloxy)-5-hydroxy-2(5H)-Furanone als antiinflammatorische Mittel
US4673668A (en) Aminonaphthacene derivatives
US4797391A (en) ((5,6-dichloro-3-oxo-9,9a-disubstituted-2,3,9,9a-tetrahydrofluoren-7-yl)oxy)alkanoic acids and alkanimidamides
US4775695A (en) Substituted amidinoalkoxy and amidinoalkylamino indanones and salts thereof
DE60005300T2 (de) 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion-inhibitoren
EP0292023A2 (de) Pyrimidinderivate
Nelson et al. Stereochemical analogs of a muscarinic, ganglionic stimulant. 2. The cis and trans olefinic, epoxide, and cyclopropane analogs related to 4-[N-(3-chlorophenyl) carbamoyloxy]-2-butynyltrimethylammonium chloride
US4312882A (en) Thienyoxy and furyl containing analogs of prostacyclin and their use as medicaments
EP0001270A1 (de) Neue Prostacyclin-Analoga, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Behandlung von Herzkreislauf-Krankheiten
US4241052A (en) Novel nitrosourea compounds and process for preparing the same
CN111620816A (zh) 螺桨烷类衍生物、其制备方法、药物组合物和用途
EP0004335A2 (de) Neue Analoga von Prostacyclin, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0060099A1 (en) Antiviral agents, their preparation and use
RU2024515C1 (ru) Способ получения полициклических биоцидных соединений или их солей
US4810727A (en) Chrysene compound

Legal Events

Date Code Title Description
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1997 00014, 970228

CTFG Supplementary protection certificate (spc) issued

Free format text: CA 1997 00014, 970228, EXPIRES: 20090925

PUP Patent expired